iBio Further Expands Tech Stack With ShieldTx; Enhances Immuno-Oncology Development Pipeline With Conditionally Activated MUC16xCD3 Bispecific
Portfolio Pulse from Benzinga Newsdesk
iBio, Inc. (IBIO) has announced the expansion of its AI-powered technology stack with the launch of ShieldTx, a patent-pending antibody masking technology. This technology is designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. The company used ShieldTx to develop masks for its MUC16-targeted bispecific antibody candidates, which were previously developed using iBio's patented Epitope Steering and EngageTx™ AI Platforms. The new technology could potentially increase the safety and developability of therapeutic antibodies for difficult targets and modes of action.
November 01, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
iBio's launch of ShieldTx, a patent-pending antibody masking technology, could potentially increase the safety and developability of therapeutic antibodies for difficult targets and modes of action. This could enhance the company's immuno-oncology development pipeline and potentially boost its market position.
The launch of ShieldTx represents a significant expansion of iBio's technology stack. This could potentially increase the safety and developability of therapeutic antibodies for difficult targets and modes of action, which could enhance the company's immuno-oncology development pipeline. This could potentially boost iBio's market position and make it more competitive in the biotech industry.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100